| abstract |
Method of treating a mammalian patient suffering from or predisposed to suffering from a disease characterized by anaphylactic, respiratory hyperresponsiveness or an inflammatory response, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis , inflammatory gastrointestinal disease or rheumatoid arthritis, said method comprising administering to said patient an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing about 0.005 to about 1.0 mg per kilogram of patient body weight ultra-low molecular weight heparin (ULMWH) or other sulfated polysaccharides having an average molecular weight of about 1000 to about 3000D. Suitable inhalants and other pharmaceutical compositions for use in this new method of treatment are also disclosed. |